Stem Cell Transplant for Fanconi Anemia

This trial explores a new treatment for Fanconi Anemia (FA), a rare genetic disorder affecting blood cell production, by performing a stem cell transplant while the baby is still in the womb. Researchers aim to determine if this method, known as IUHSCT (in utero hematopoietic stem cell transplantation), is safe and effective for fetuses diagnosed with FA. The trial seeks fetuses between 19 and 28 weeks of gestation diagnosed with FA through specific genetic tests and certain family history or ultrasound findings. As a Phase 1 and Phase 2 trial, this research focuses on understanding the treatment's mechanism and measuring its effectiveness in an initial, smaller group of patients, offering a unique opportunity to be among the first to benefit from this innovative approach.

The trial information does not specify whether participants need to stop taking their current medications. However, if you are a maternal participant, you cannot be on anticoagulants or have an opioid use disorder.

Research suggests that In Utero Hematopoietic Stem Cell Transplantation (IUHSCT) might safely treat unborn babies with Fanconi anemia. Studies have shown that this procedure can occur before birth as a one-time outpatient treatment, without the need for immune-suppressing drugs, often resulting in fewer side effects. Although researchers are still studying the procedure, early results indicate it could safely stabilize blood and immune systems. However, since this treatment is currently in early stages of testing (Phase 1 and Phase 2 trials), information on its long-term safety in humans remains limited. Still, preclinical studies show promise for its safety and effectiveness.¹²³⁴⁵

Unlike the standard treatments for Fanconi Anemia, which typically involve bone marrow transplants after birth, this investigational approach uses in utero hematopoietic stem cell transplantation (IUHSCT). This method is unique because it delivers stem cells directly to the fetus during pregnancy, potentially correcting the blood cell production issues before birth. By using maternal bone marrow-derived stem cells, this technique aims to reduce the risk of transplant rejection. Researchers are excited about this treatment because it could offer a new way to manage Fanconi Anemia early on, potentially improving outcomes and decreasing the need for postnatal interventions.

Research has shown that treating Fanconi anemia before birth with in utero hematopoietic stem cell transplantation (IUHSCT) could be promising. This trial will investigate IUHSCT, which studies suggest might be safe and could potentially cure the condition. Patients who underwent IUHSCT in previous studies showed long-term positive results, indicating it can help fix the bone marrow problems caused by Fanconi anemia. This treatment uses special donor cells, which can transform into different cell types, to help the unborn baby's body fight the disease. Although more research is needed, early results are encouraging.¹²⁴⁵⁶